StreetInsider.com News Articles

INOVIO to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

PLYMOUTH MEETING, Pa., Sept. 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences:

INOVIO to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 16:05:00 -0400

H.C. Wainwright Reiterates Neutral Rating on Inovio Pharmaceuticals (INO)

Thu, 13 Aug 2026 07:04:32 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Neutral rating and $2.50 price target on Inovio Pharmaceuticals (NASDAQ: INO).

The analyst commented: "Yesterday, INOVIO reported its 2Q26 financial results. Net loss was $6.0M, or ($0.07) per share, less than our estimated loss of $20.0M due to change in fair value of warrant liabilities. Importantly, FDA has completed the late-cycle review meeting and all scheduled pre-licensure inspections for INO-3107, including clinical, drug manufacturing, in-house drug testing and the delivery device facility. One observation was reported, and the company believes it has been appropriately addressed. FDA also held the previously requested informal clinical meeting

Jefferies Upgrades Inovio Pharmaceuticals (INO) to Buy

Thu, 13 Aug 2026 04:37:55 -0400

Jefferies analyst Roger Song upgraded Inovio Pharmaceuticals (NASDAQ: INO) from Hold to Buy with a price target of $3.00 (from $1.80).

The analyst comments: “We caught up w/ mgmt. Update was incrementally positive as FDA review on RRP remains on track for the 10/30/26 PDUFA, w/ key review milestones completed and no new issues disclosed. Mgmt reiterated confidence in accelerated approval eligibility and expects confirmatory feedback before PDUFA. Co continues to advance launch preparations. Cash was ~$37M (excl ~$18M in Jul) and runway into late 1Q27, covering potential launch of '3107. PT to $3, Upgrade to Buy.

Primary focus of 2Q remained

Jefferies Upgrades Inovio Pharmaceuticals (INO) to Buy

Thu, 13 Aug 2026 04:37:55 -0400

Jefferies analyst Roger Song upgraded Inovio Pharmaceuticals (NASDAQ: INO) from Hold to Buy with a price target of $3.00 (from $1.80).

Primary focus of 2Q remained

Inovio Pharma (INO) Tops Q2 EPS by 18c

Wed, 12 Aug 2026 16:38:10 -0400

Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.07), $0.18 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

Form 8-K INOVIO PHARMACEUTICALS, For: Aug 12

Wed, 12 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260812/26912856.html

Form 8-K INOVIO PHARMACEUTICALS, For: Aug 12

Wed, 12 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260812/26912856.html

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:05:00 -0400

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026
Commercial preparations advancing in anticipation of potential product launch for INO-3107
Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China
Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences
Current cash, cash equivalents,

Form 10-Q INOVIO PHARMACEUTICALS, For: Jun 30

Wed, 12 Aug 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20260812/26912561.html

Form 10-Q INOVIO PHARMACEUTICALS, For: Jun 30

Wed, 12 Aug 2026 16:01:00 -0400
si-local-file:///var/storage/secattach/20260812/26912561.html

Form SCHEDULE 13G/A INOVIO PHARMACEUTICALS, Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:03:00 -0400
si-local-file:///var/storage/secattach/20260812/26911217.html

Form SCHEDULE 13G/A INOVIO PHARMACEUTICALS, Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:03:00 -0400
si-local-file:///var/storage/secattach/20260812/26911217.html

Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 07 Aug 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260807/26891186.html